| Over a week ago |
|
Hot Stocks
|
Pliant Therapeutics… Pliant Therapeutics announced Lily Cheung as its Chief Human Resources Officer. Cheung brings over 25 years of Human Resources experience across the technology and biopharmaceutical industries, including more than 15 years of commercial-stage experience. Cheung joins Pliant from Synthekine, a privately held biotechnology company. ShowHide Related Items >><< - 01/22/23
- Pliant Therapeutics announces data from INTEGRIS-IPF Phase 2a trial
- 12/15/22
- Pliant Therapeutics receives Orphan Drug Designation from EMA for Bexotegrast
- 09/15/22
- Pliant Therapeutics announces appointment of Knobil to board of directors
- 09/01/22
- Pliant announces 'positive' safety review of PLN-74809 study to treat IPF
- 01/24/23 SVB Securities
- Pliant Therapeutics price target raised to $45 from $33 at SVB Securities
- 01/24/23 Citi
- Pliant Therapeutics price target raised to $55 from $36 at Citi
- 01/23/23 JPMorgan
- Pliant Therapeutics price target raised to $51 from $42 at JPMorgan
- 01/23/23 Cantor Fitzgerald
- Pliant Therapeutics price target raised to $52 from $40 at Cantor Fitzgerald
- 11/08/22
- Pliant Therapeutics reports Q3 EPS (65c), consensus (74c)
- 08/08/22
- Pliant Therapeutics reports Q2 EPS (82c), consensus (81c)
|
|
Syndicate
|
The deal size was… The deal size was increased to $250M from $175M and priced below last closing price of $32.94. JPMorgan and Piper Sandler are acting as joint book running managers for the offering. ShowHide Related Items >><< - 01/22/23
- Pliant Therapeutics announces data from INTEGRIS-IPF Phase 2a trial
- 12/15/22
- Pliant Therapeutics receives Orphan Drug Designation from EMA for Bexotegrast
- 09/15/22
- Pliant Therapeutics announces appointment of Knobil to board of directors
- 09/01/22
- Pliant announces 'positive' safety review of PLN-74809 study to treat IPF
- 01/24/23 SVB Securities
- Pliant Therapeutics price target raised to $45 from $33 at SVB Securities
- 01/24/23 Citi
- Pliant Therapeutics price target raised to $55 from $36 at Citi
- 01/23/23 JPMorgan
- Pliant Therapeutics price target raised to $51 from $42 at JPMorgan
- 01/23/23 Cantor Fitzgerald
- Pliant Therapeutics price target raised to $52 from $40 at Cantor Fitzgerald
- 11/08/22
- Pliant Therapeutics reports Q3 EPS (65c), consensus (74c)
- 08/08/22
- Pliant Therapeutics reports Q2 EPS (82c), consensus (81c)
|
|
Recommendations
|
SVB Securities analyst… SVB Securities analyst Thomas Smith raised the firm's price target on Pliant Therapeutics to $45 from $33 to reflect better-than-expected 320mg dose cohort results of bexotegrast in the Phase 2a INTEGRIS-IPF study that reinforce confidence that bexo will compete for a best-in-class profile in IPF. The firm has an Outperform rating on the shares. ShowHide Related Items >><< - $30.24 /
+7.585 (+33.48%) - 01/22/23
- Pliant Therapeutics announces data from INTEGRIS-IPF Phase 2a trial
- 12/15/22
- Pliant Therapeutics receives Orphan Drug Designation from EMA for Bexotegrast
- 09/15/22
- Pliant Therapeutics announces appointment of Knobil to board of directors
- 09/01/22
- Pliant announces 'positive' safety review of PLN-74809 study to treat IPF
- $30.24 /
+7.585 (+33.48%) - 01/24/23 Citi
- Pliant Therapeutics price target raised to $55 from $36 at Citi
- 01/23/23 JPMorgan
- Pliant Therapeutics price target raised to $51 from $42 at JPMorgan
- 01/23/23 Cantor Fitzgerald
- Pliant Therapeutics price target raised to $52 from $40 at Cantor Fitzgerald
- 12/13/22 Stifel
- Pliant Therapeutics initiated with a Buy at Stifel
- $30.24 /
+7.585 (+33.48%) - 11/08/22
- Pliant Therapeutics reports Q3 EPS (65c), consensus (74c)
- 08/08/22
- Pliant Therapeutics reports Q2 EPS (82c), consensus (81c)
|
|
Recommendations
|
Citi analyst David… Citi analyst David Lebowitz raised the firm's price target on Pliant Therapeutics to $55 from $36 and keeps a Buy rating on the shares. The company released interim results from 320mg bexotegrast cohort in Phase IIa trial in idiopathic pulmonary fibrosis showing promising safety and efficacy as an add-on therapy to standard of care, the analyst tells investors in a research note. The firm updated the model to reflect bexotegrast's higher probability of success. ShowHide Related Items >><< - $30.24 /
+7.585 (+33.48%) - 01/22/23
- Pliant Therapeutics announces data from INTEGRIS-IPF Phase 2a trial
- 12/15/22
- Pliant Therapeutics receives Orphan Drug Designation from EMA for Bexotegrast
- 09/15/22
- Pliant Therapeutics announces appointment of Knobil to board of directors
- 09/01/22
- Pliant announces 'positive' safety review of PLN-74809 study to treat IPF
- $30.24 /
+7.585 (+33.48%) - 01/23/23 JPMorgan
- Pliant Therapeutics price target raised to $51 from $42 at JPMorgan
- 01/23/23 Cantor Fitzgerald
- Pliant Therapeutics price target raised to $52 from $40 at Cantor Fitzgerald
- 12/13/22 Stifel
- Pliant Therapeutics initiated with a Buy at Stifel
- 12/07/22 JPMorgan
- Pliant Therapeutics initiated with an Overweight at JPMorgan
- $30.24 /
+7.585 (+33.48%) - 11/08/22
- Pliant Therapeutics reports Q3 EPS (65c), consensus (74c)
- 08/08/22
- Pliant Therapeutics reports Q2 EPS (82c), consensus (81c)
|
|
On The Fly
|
Check out this evening's… ShowHide Related Items >><< - 01/23/23
- Zions Bancorp reports Q4 net interest income up 30% y/y at $720M
- 10/28/22
- Zions Bancorp approves Q4 share repurchase for up to $50M
- 07/29/22
- Zions Bancorp board authorizes Q3 share repurchase of up to $50M
- $30.24 /
+7.585 (+33.48%) - 01/22/23
- Pliant Therapeutics announces data from INTEGRIS-IPF Phase 2a trial
- 12/15/22
- Pliant Therapeutics receives Orphan Drug Designation from EMA for Bexotegrast
- 09/15/22
- Pliant Therapeutics announces appointment of Knobil to board of directors
- 09/01/22
- Pliant announces 'positive' safety review of PLN-74809 study to treat IPF
- $113.83 /
+2.315 (+2.08%) - 12/21/22
- Inter Parfums subsidiary, Lacoste sign exclusive 15-year fragrance license pact
- 01/23/23
- Independent Bank authorizes up to $125M share repurchase
- 09/06/22
- Independent Bank appoints Dan Strodel as chief banking officer
- 07/29/22
- Independent Bank names Paul Langdale as CFO, replacing Michelle Hickox
- 01/23/23
- HighPeak Energy shares jump approximately 11% after announcing possible sale
- 01/23/23
- HighPeak Energy to reduce drilling operations from six to four rigs in FY23
- 01/23/23
- HighPeak Energy initiates process to evaluate strategic alternatives
- 01/23/23
- HighPeak Energy trading resumes
- 10/20/22
- Crane names Aaron Saak CEO of Crane NXT
- 08/15/22
- Crane divests Redco subsidiary to Spruce Lake Liability Management Holdco
- 08/23/22
- Concrete Pumping acquires Coastal Carolina Pumping
- 08/01/22
- Concrete Pumping upsizes asset-based lending facility to $160M
- 01/23/23
- Axcella announces regulatory path to registration of AXA1125
- 12/14/22
- Axcella announces corporate restructuring, will reduce workforce by 85%
- 09/29/22
- Axcella Health's AXA1125 shows efficacy in Phase 2b NASH trial
- 08/02/22
- Axcella Health reports results from Phase 2a investigation for AXA1125
- 12/15/22 SVB Securities
- Axcella Health downgraded to Market Perform from Outperform at SVB Securities
- 12/15/22 H.C. Wainwright
- H.C. Wainwright downgrades Axcella with discontinuation 'major detriment'
- 12/15/22 H.C. Wainwright
- Axcella Health downgraded to Neutral from Buy at H.C. Wainwright
- 11/02/22 Chardan
- Axcella Health price target lowered to $5 from $7 at Chardan
- 04/28/22 Roth MKM
- HighPeak Energy price target raised to $38.75 from $32.50 at Roth Capital
- $30.24 /
+7.585 (+33.48%) - 01/23/23 JPMorgan
- Pliant Therapeutics price target raised to $51 from $42 at JPMorgan
- 01/23/23 Cantor Fitzgerald
- Pliant Therapeutics price target raised to $52 from $40 at Cantor Fitzgerald
- 12/13/22 Stifel
- Pliant Therapeutics initiated with a Buy at Stifel
- 12/07/22 JPMorgan
- Pliant Therapeutics initiated with an Overweight at JPMorgan
- $113.83 /
+2.315 (+2.08%) - 01/06/23 DA Davidson
- Inter Parfums price target raised to $126 from $116 at DA Davidson
- 01/03/23 Piper Sandler
- Inter Parfums price target raised to $115 from $108 at Piper Sandler
- 12/23/22 DA Davidson
- Inter Parfums price target raised to $116 from $104 at DA Davidson
- 11/22/22 DA Davidson
- Inter Parfums price target raised to $104 from $98 at DA Davidson
- 12/12/22 Morgan Stanley
- Crane upgraded to Overweight from Equal Weight at Morgan Stanley
- 10/11/22 Stifel
- Crane price target lowered to $121 from $123 at Stifel
- 04/18/22 Stifel
- Crane price target lowered to $134 from $137 at Stifel
- 01/03/23 Barclays
- Zions Bancorp downgraded to Underweight from Equal Weight at Barclays
- 12/21/22 DA Davidson
- DA Davidson upgrades Zions Bancorp to Buy on low valuation
- 12/20/22 DA Davidson
- Zions Bancorp upgraded to Buy from Neutral at DA Davidson
- 12/13/22 JPMorgan
- Zions Bancorp price target lowered to $49 from $55 at JPMorgan
- 12/09/22 Truist
- Independent Bank price target lowered to $70 from $74 at Truist
- 10/26/22 Truist
- Independent Bank price target lowered to $74 from $80 at Truist
- 10/26/22 Hovde Group
- Independent Bank downgraded to Market Perform from Outperform at Hovde Group
- 09/16/22 Piper Sandler
- Independent Bank price target lowered to $75 from $78 at Piper Sandler
EFSC Enterprise Financial - 10/26/22 DA Davidson
- Enterprise Financial upgraded to Buy from Neutral at DA Davidson
- 03/21/22 Boenning & Scattergood
- Enterprise Financial initiated with an Outperform at Boenning & Scattergood
- 01/23/23
- Zions Bancorp reports Q4 EPS $1.84, consensus $1.64
- 01/23/23
- Notable companies reporting after market close
- 10/24/22
- Zions Bancorp reports Q3 EPS $1.40, consensus $1.58
- 10/24/22
- Notable companies reporting after market close
- $30.24 /
+7.585 (+33.48%) - 11/08/22
- Pliant Therapeutics reports Q3 EPS (65c), consensus (74c)
- 08/08/22
- Pliant Therapeutics reports Q2 EPS (82c), consensus (81c)
- $113.83 /
+2.315 (+2.08%) - 01/23/23
- Inter Parfums raises FY23 EPS view to $3.75 from $3.70, consensus $3.74
- 01/23/23
- Inter Parfums sees FY22 EPS roughly $3.60, consensus $3.55
- 01/23/23
- Inter Parfums reports Q4 revenue $311M, consensus $290.67M
- 01/04/23
- Inter Parfums raises FY23 EPS view to $3.75 from $3.70, consensus $3.70
- 01/23/23
- Independent Bank reports Q4 adjusted EPS $1.20, consensus $1.28
- 10/24/22
- Independent Bank reports Q3 adjusted EPS $1.33, consensus $1.33
- 07/25/22
- Independent Bank reports Q2 EPS $1.27, consensus $1.23
- 11/14/22
- HighPeak Energy reports Q3 EPS 85c vs 8c last year
EFSC Enterprise Financial - 01/23/23
- Enterprise Financial reports Q4 EPS $1.58, consensus $1.35
- 10/24/22
- Enterprise Financial reports Q3 EPS $1.32, consensus $1.24
- 07/25/22
- Enterprise Financial reports Q2 EPS $1.19, consensus $1.12
- 01/23/23
- Crane sees FY23 EPS $3.40-$3.70 post separation
- 01/23/23
- Crane reports Q4 EPS $2.13, consensus $1.90
- 10/24/22
- Crane narrows FY22 EPS view to $7.58-$7.72 from $7.45-$7.85, consensus $7.75
- 10/24/22
- Crane reports Q3 adjusted EPS $1.86, consensus $1.85
- 01/23/23
- Concrete Pumping reports Q4 EPS 14c, consensus 12c
- 09/08/22
- Concrete Pumping reports Q3 EPS 24c, consensus 12c
- 11/01/22
- Axcella Health reports Q3 EPS (34c), consensus (38c)
- 08/12/22
- Axcella Health reports Q2 EPS (40c), consensus (38c)
|
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 12/29/22
- Cathie Wood's ARK Investment bought 57K shares of Zoom Video today
- 11/21/22
- Zoom Video sees Q4 deferred revenue up roughly 2%-3% y/y
- 11/09/22
- Cathie Wood's ARK Investment bought 149K shares of Zoom Video today
- 11/09/22
- Verint Customer Engagement Platform to integrate with Zoom Contact Center
- 01/23/23
- Xylem falls -9.9%
- 01/23/23
- Xylem falls -8.7%
- 01/23/23
- Evoqua Water jumps 14% to $46.71 after Xylem buyout offer
- 01/23/23
- Xylem to acquire Evoqua Water in $7.5B all-stock transaction
- 01/13/23
- Wells Fargo sees low to mid-single digit loan growth in FY23
- 01/13/23
- Wells Fargo sees FY23 NII growth roughly 10% y/y
- 01/13/23
- Wells Fargo says credit performance remains strong across all businesses
- 10/26/22
- Kioxia, Western Digital open semiconductor fabrication facility Fab7 in Japan
- 08/31/22
- Western Digital, Micron lower in pre-market after Seagate guidance cut
- 08/15/22
- Elliott buys Pinterest, exits Twitter in Q2
- 08/05/22
- Western Digital drops 8% to $45.80 after Q1 guidance misses estimates
- $59.37 /
+12.645 (+27.06%) - 01/23/23
- Wayfair rises 25.3%
- 01/23/23
- Wayfair rises 25.4%
- 01/23/23
- Wayfair rises 18.8%
- 01/20/23
- Wayfair rises 21.7%
- 12/04/22
- Fly Intel: Top five weekend stock stories
- 09/09/22
- Tapestry announces long-term financial targets
- 08/04/22
- Tapestry COO Tom Glaser retires, Scott Roe to succeed
- 01/23/23
- Synchrony expects decline in net charge-off rate in Q3, normalization path in Q4
- 01/23/23
- Synchrony sees FY23 NIM 15%-15.25%
- 01/23/23
- Synchrony sees long-term ROA 2.5%, ROTCE 28%+
- 01/11/23
- Synchrony reestablishes partnership with Bassett Furniture
- 01/23/23
- Sumo Logic up 25% after Information's report on PE approaches
- 01/23/23
- Sumo Logic trading resumes
- 01/23/23
- Sumo Logic trading halted, volatility trading pause
- 12/08/22
- Sumo Logic announces availability of Cloud SOAR in AWS Tokyo region
- 01/23/23
- Spotify: Alex Norstrom, Gustav Soderstrom appointed co-presidents
- 01/23/23
- Spotify announces reduction in employee base by about 6%
- 01/23/23
- Spotify's Chief Content & Advertising Business Officer Dawn Ostroff to leave
- 01/23/23
- Spotify announces reduction in employee base by about 6%
- 12/29/22
- Bridgeline, Shopify partner for prescriptive marketing dashboard eCommerce360
- 12/13/22
- Nogin names Bonham-Carter as Chief Revenue Officer
- 11/29/22
- Shopify reports Black Friday Cyber Monday weekend sales up 19% y/y
- 11/28/22
- Shopify rises 8.8%
- 01/09/23
- Qualcomm down 1% after Bloomberg report on Apple taking modem in-house
- 01/05/23
- Iridium to partner t with Qualcomm on satellite messaging and emergency services
- 01/04/23
- Visteon, Qualcomm collaborate on development of digital cockpit
- 11/02/22
- Qualcomm falls 7% to $104.90 after Q1 guidance misses estimates
- 01/12/23
- PayPal's Xoom service expands debit card deposit feature
- 01/09/23
- Netflix names Jeffrey Karbowski as Principal Accounting Officer
- 12/14/22
- ConsenSys teams with PayPal for new way to buy crypto in MetaMask
- 12/07/22
- PayPal expands cryptocurrency buy, sell and hold service to Luxembourg
- $30.24 /
+7.585 (+33.48%) - 01/22/23
- Pliant Therapeutics announces data from INTEGRIS-IPF Phase 2a trial
- 12/15/22
- Pliant Therapeutics receives Orphan Drug Designation from EMA for Bexotegrast
- 09/15/22
- Pliant Therapeutics announces appointment of Knobil to board of directors
- 09/01/22
- Pliant announces 'positive' safety review of PLN-74809 study to treat IPF
- 01/20/23
- Peoples Bancorp board declares special cash dividend of 15c per share
NWBI Northwest Bancshares - 01/23/23
- Northwest Bancshares to reduce workforce about 12%
- 08/18/22
- Northwest Bancshares and Northwest Bank name Louis Torchio as CEO
- 01/12/23
- Lucid Group reports vehicle production up 53% sequentially in Q4 to 3,493
- 12/21/22
- Lucid Group begins deliveries of Lucid Air in Europe
- 12/19/22
- Lucid Group jumps 7% to $7.74 after announcing $1.515B capital raise
- 12/19/22
- Lucid Group announces capital raise of $1.515B
- 01/20/23
- JPMorgan Asset Management receives approval for 100% ownership of China JV
- 01/13/23
- JPMorgan says continues to expect 17% ROTCE in 2023
- 01/13/23
- JPMorgan says targeting potential $12B in share buybacks in 2023
- 01/13/23
- JPMorgan says investment banking pipeline 'relatively robust'
- 01/18/23
- EU passenger car registrations up 12.8% in December
- 01/10/23
- RMI launches virtual power plant partnership with GM, Google, Ford
- 01/05/23
- Ford reports December U.S. sales 179,279, up 3.2%
- 12/20/22
- CDK Global integrates Ford and Lincoln vehicle build data into API
- 01/23/23
- Association of Pickleball Professionals announces broadcast deals with CBS, ESPN
- 01/17/23
- Disney says Peltz 'lacks skills and experience' to help board deliver value
- 01/16/23
- Top five weekend stock stories
- 12/29/22
- Nevada reports November statewide gaming win down 7.62% to $1.22B
- 12/21/22
- Caesars Sportsbook launches sports betting at Casino Metro
- 12/20/22
- New Jersey reports November gaming revenue up 0.3% to $441.1M
- 12/05/22
- NFL, Genius Sports expand partnership to provide video streams to Caesars
- 01/22/23
- Fly Intel: Top five weekend stock stories
- 01/12/23
- Walmart enters partnership with Salesforce to provide solutions for retailers
- 01/11/23
- Salesforce Security CTO says leaving to join Evolution Equity Partners
- 01/04/23
- Salesforce up 4% to $139.85 after announcing restructuring
CPRX Catalyst Pharmaceuticals - 01/23/23
- Catalyst comments on the FDA's position on orphan drug exclusivity
- 01/23/23
- Catalyst Pharmaceuticals notified of ANDA filing for FIRDAPSE
- 12/19/22
- Catalyst to buy U.S. commercial rights for FYCOMPA from Eisai for $160M
- 09/29/22
- Catalyst Pharmaceuticals announces FDA approval of sNDA for FIRDAPSE
- 01/23/23
- Bank of Hawaii CFO sees having reached near-term margin peak
- 01/20/23
- Baker Hughes reports U.S. rig count down 4 to 771 rigs
- 01/20/23
- Baker Hughes reports U.S. rig count down 4 to 771 rigs
- 01/17/23
- Archer announces term sheet to potentially acquire Baker Hughes unit in U.K.
- 01/13/23
- Baker Hughes reports U.S. rig count up 3 to 775 rigs
- 01/13/23
- Bank of America sees mid-single digit loan growth next year
- 01/13/23
- Bank of America sees Q1 NII around $14.4B
- 01/13/23
- Bank of America sees net charge-offs moving to pre-pandemic levels
- 01/13/23
- Bank of America starting to see stabilization in deposits, says CEO
- $47.29 /
+6.245 (+15.22%) - 01/23/23
- Evoqua Water rises 13.2%
- 01/23/23
- Evoqua Water rises 11.2%
- 01/23/23
- Evoqua Water rises 13.0%
- 11/20/22
- Fly Intel: Top five weekend stock stories
- 10/27/22
- Stonepeak increases investment in American Tower's data center business
- 10/03/22
- American Tower EVP/General Counsel Ed DiSanto to step down
- 08/31/22
- American Tower, Verizon sign new lease agreement
- 01/20/23
- AMD identified as respondent in ITC investigation of certain integrated circuits
- 01/19/23
- AMD adaptive computing tech enables DENSO LiDAR system
- 01/11/23
- AMD CFO Devinder Kumar to retire, Jean Hu appointed new CFO
- 12/20/22
- EU opens antitrust probe into Broadcom's proposed $61B VMware bid
- 01/23/23
- Agenus presents clinical data from MSS CRC 70 patient cohort of a Phase 1b
- 11/17/22
- Agenus announces expanded data from Phase 1 study of botensilimab, balstilimab
- 11/14/22
- Agenus reports data on botensilimab/balstilimab combination in nine cancer types
- 10/13/22
- GSK vaccine candidate with Agenus' Stimulon shows 82.6% efficacy in RSV
- 01/20/23
- Apple appeals UK competition watchdog investigation
- 01/19/23
- Amazon raising prices for Music subscription plans
- 01/18/23
- Apple TV+ says 'Ted Lasso' season three coming spring 2023
- 01/18/23
- Apple announces HomePod 2nd generation, available February 3
- 01/24/23 Morgan Stanley
- Xylem-Evoqua deal timing a surprise, but not tie-up, says Morgan Stanley
- 01/24/23 Loop Capital
- Xylem deal for Evoqua priced 'high' but 'great' long-term fit, says Loop Capital
- 01/24/23 Stifel
- Xylem upgraded to Buy from Hold at Stifel
- 01/23/23 Stifel
- Xylem stock reaction to Evoqua deal 'confounding,' says Stifel
- $47.29 /
+6.245 (+15.22%) - 01/23/23 Deutsche Bank
- Salesforce price target lowered to $190 from $200 at Deutsche Bank
- 01/20/23 Cowen
- Salesforce downgraded to Market Perform at Cowen with disruption risk elevated
- 01/20/23 Cowen
- Salesforce downgraded to Market Perform from Outperform at Cowen
- 01/17/23 DA Davidson
- Salesforce initiated with a Neutral at DA Davidson
- 01/23/23 Piper Sandler
- Spotify workforce reduction to be viewed positively, says Piper Sandler
- 01/17/23 Truist
- Truist sees expectations for Spotify subs and active users as 'reasonable'
- 01/12/23 Jefferies
- Spotify downgraded to Hold from Buy at Jefferies
- 01/05/23 UBS
- Spotify price target lowered to $100 from $142 at UBS
- 01/24/23 Evercore ISI
- Baker Hughes price target raised to $37 from $33 at Evercore ISI
- 01/24/23 Susquehanna
- Baker Hughes price target raised to $40 from $35 at Susquehanna
- 01/19/23 Benchmark
- Baker Hughes initiated with a Buy at Benchmark
- 11/18/22 Piper Sandler
- Baker Hughes price target raised to $34 from $30 at Piper Sandler
- 01/24/23 BMO Capital
- Synchrony price target lowered to $53 from $56 at BMO Capital
- 01/24/23 JMP Securities
- Synchrony price target raised to $42 from $39 at JMP Securities
- 01/24/23 Citi
- Synchrony price target raised to $45 from $44 at Citi
- 01/10/23 JPMorgan
- Synchrony price target lowered to $36 from $39 at JPMorgan
- $59.37 /
+12.645 (+27.06%) - 01/23/23 Wedbush
- Wayfair upgraded to Outperform from Neutral at Wedbush
- 01/23/23 BofA
- BofA double upgrades Wayfair to Buy on 'significant improvement'
- 01/23/23 BofA
- Wayfair upgraded to Buy from Underperform at BofA
- 01/23/23 Oppenheimer
- Wayfair price target lowered to $70 from $110 at Oppenheimer
- 01/24/23 Cowen
- AMD remains in a very strong competitive position, says Cowen
- 01/24/23 Bernstein
- AMD downgraded to Market Perform from Outperform at Bernstein
- 01/23/23 Truist
- AMD price target raised to $79 from $70 at Truist
- 01/23/23 Barclays
- AMD upgraded to Overweight from Equal Weight at Barclays
- 01/23/23 Barclays
- Qualcomm upgraded to Overweight from Equal Weight at Barclays
- 01/18/23 Citi
- Citi opens 'negative catalyst watch' on Intel and Qualcomm
- 01/11/23 KeyBanc
- KeyBanc says iPhone survey shows supply partial recovery, some shortages remain
- 01/10/23 Piper Sandler
- Piper Sandler sees no strategic reason for Apple to insource Wi-Fi combo chip
- 01/23/23 MKM Partners
- MKM Partners cuts Zoom Video to Neutral, sees limited upside in Meetings growth
- 01/23/23 MKM Partners
- Zoom Video downgraded to Neutral from Buy at MKM Partners
- 01/17/23 Piper Sandler
- Zoom Video price target lowered to $75 from $77 at Piper Sandler
- 12/15/22 Wedbush
- Wedbush initiates Zoom Video with a Neutral and $80 price target
- 01/23/23 Deutsche Bank
- Shopify upgraded to Buy from Hold at Deutsche Bank
- 01/19/23 Truist
- Shopify price target raised to $41 from $35 at Truist
- 01/18/23 DA Davidson
- Shopify assumed with a Neutral at DA Davidson
- 01/17/23 Loop Capital
- Shopify price target raised to $39 from $36 at Loop Capital
- 01/23/23 Barclays
- Capri Holdings price target raised to $72 from $56 at Barclays
- 01/23/23 Barclays
- Tapestry downgraded to Equal Weight from Overweight at Barclays
- 12/20/22 Raymond James
- Tapestry initiated with an Outperform at Raymond James
- 12/19/22 Raymond James
- Tapestry initiated with an Outperform at Raymond James
- 01/24/23 BofA
- Banks' potential new online wallet unlikely to threaten PayPal, says BofA
- 01/17/23 Citi
- Wells Fargo price target raised to $52 from $48 at Citi
- 01/17/23 Piper Sandler
- Wells Fargo downgraded to Neutral from Overweight at Piper Sandler
- 01/17/23 Jefferies
- Wells Fargo downgraded to Hold from Buy at Jefferies
- 01/17/23 Citi
- Bank of America price target raised to $38 from $36 at Citi
- 01/17/23 Piper Sandler
- Bank of America downgraded to Underweight from Neutral at Piper Sandler
- 01/10/23 Odeon Capital
- Bank of America upgraded to Buy from Hold at Odeon Capital
- 01/17/23 Citi
- JPMorgan price target raised to $165 from $150 at Citi
- 01/17/23 Piper Sandler
- JPMorgan price target raised to $157 from $150 at Piper Sandler
- 01/06/23 Deutsche Bank
- JPMorgan downgraded to Hold with $145 target at Deutsche Bank
- 01/23/23 Bernstein
- PayPal's 2023 earnings appear largely de-risked, says Bernstein
- 01/18/23 Jefferies
- PayPal price target lowered to $85 from $90 at Jefferies
- 01/18/23 SMBC Nikko
- PayPal downgraded to Underperform from Neutral at SMBC Nikko
- 01/23/23 Exane BNP Paribas
- Western Digital upgraded to Neutral from Underperform at Exane BNP Paribas
- 01/06/23 Benchmark
- Western Digital upgraded to Hold at Benchmark after Kioxia merger talks report
- 01/06/23 Benchmark
- Western Digital upgraded to Hold from Sell at Benchmark
- 01/05/23 Deutsche Bank
- Western Digital, Kioxia deal makes 'a lot of sense,' says Deutsche Bank
- 01/11/23 Goldman Sachs
- Goldman continues to prefer Tesla and GM among automakers
- 12/21/22 Morgan Stanley
- Tesla shedding $600B of value presents buying opportunity, says Morgan Stanley
- 12/05/22 Jefferies
- Fox Factory price target raised to $135 from $120 at Jefferies
- 12/05/22 Jefferies
- Polaris price target raised to $106 from $100 at Jefferies
- 01/24/23 Bernstein
- Demand for Apple iPhones should decline in 2023, says Bernstein
- 01/23/23 UBS
- Apple's iPhone softness offset by improving currency factors, says UBS
- 01/23/23 Deutsche Bank
- Apple price target lowered to $160 from $170 at Deutsche Bank
- 01/19/23 JPMorgan
- Apple facing 'tough setup' for upcoming earnings, says JPMorgan
- 11/18/22 Barrington
- Dolby downgraded to Market Perform from Outperform at Barrington
- 10/14/22 Tigress Financial
- Dolby price target lowered to $116 from $128 at Tigress Financial
- 06/08/22
- Baird to hold a conference
- 01/24/23 Wells Fargo
- Wells Fargo bullish on Disney, says Iger 'will come out swinging'
- 01/17/23 Huber Research
- Disney initiated with an Overweight at Huber Research
- 01/17/23 Truist
- Truist names Disney Top Idea for 2023, price target lowered to $120 from $125
- 01/17/23 Wells Fargo
- ESPN/ABC potential spin would make sense, add value, says Wells Fargo
- $30.24 /
+7.585 (+33.48%) - 01/24/23 SVB Securities
- Pliant Therapeutics price target raised to $45 from $33 at SVB Securities
- 01/24/23 Citi
- Pliant Therapeutics price target raised to $55 from $36 at Citi
- 01/23/23 JPMorgan
- Pliant Therapeutics price target raised to $51 from $42 at JPMorgan
- 01/23/23 Cantor Fitzgerald
- Pliant Therapeutics price target raised to $52 from $40 at Cantor Fitzgerald
- 01/22/23 Citi
- Lucid Group resumed with a Buy at Citi
- 01/12/23 Cantor Fitzgerald
- Lucid's Q4 production pre-announcement 'encouraging, says Cantor Fitzgerald
- 01/12/23 Evercore ISI
- Evercore ISI says Lucid FY/Q4 production serves as glimmer of execution progress
- 12/15/22 BofA
- Lucid Group resumed with a Buy at BofA
CPRX Catalyst Pharmaceuticals - 01/23/23 Piper Sandler
- ANDA filing for generic Firdapse not a surprise, says Piper Sandler
- 01/19/23 Truist
- Catalyst Pharmaceuticals price target raised to $22 from $18 at Truist
- 12/21/22 H.C. Wainwright
- Catalyst Pharmaceuticals price target raised to $24 from $18 at H.C. Wainwright
- 12/19/22 Piper Sandler
- Catalyst Pharmaceuticals price target raised to $20 from $18 at Piper Sandler
- 12/08/22 EF Hutton
- Agenus initiated with a Buy at EF Hutton
- 09/27/22 SMBC Nikko
- Agenus initiated with an Outperform at SMBC Nikko
- 03/03/22 B. Riley
- Agenus price target lowered to $8 from $11 at B. Riley
- 03/02/22 H.C. Wainwright
- Agenus price target raised to $14 from $12 at H.C. Wainwright
- 01/23/23 KeyBanc
- American Tower downgraded to Sector Weight from Overweight at KeyBanc
- 01/22/23 Citi
- American Tower buyout of Cellnex a possibility, says Citi
- 01/13/23 Truist
- American Tower price target lowered to $275 from $325 at Truist
- 01/12/23 Deutsche Bank
- American Tower upgraded to Buy from Hold at Deutsche Bank
- 01/24/23 Stifel
- Stifel ups Caesars price target, says time for investors to revisit
- 01/24/23 Barclays
- Caesars price target raised to $66 from $65 at Barclays
- 01/04/23 BofA
- Caesars price target lowered to $50 from $55 at BofA
- 12/14/22 BofA
- Caesars downgraded to Neutral at BofA with growth momentum levelling out
NWBI Northwest Bancshares - 09/29/22 Janney Montgomery Scott
- Janney starts Northwest Bancshares with a Neutral, sees $15 fair value
- 09/29/22 Janney Montgomery Scott
- Northwest Bancshares initiated with a Neutral at Janney Montgomery Scott
- 07/11/22 B. Riley
- Northwest Bancshares price target lowered to $11 from $14 at B. Riley
- 05/06/22 Piper Sandler
- Northwest Bancshares downgraded to Underweight from Neutral at Piper Sandler
- 01/23/23 Keefe Bruyette
- Keefe keeps Market Perform on Bank of Hawaii, says margin likely under pressure
- 10/25/22 DA Davidson
- Bank of Hawaii price target lowered to $76 from $80 at DA Davidson
- 07/11/22 Jefferies
- Bank of Hawaii price target lowered to $79 from $87 at Jefferies
- 01/24/23 William Blair
- Sumo Logic takeout could be double share price, says William Blair
- 01/24/23 Jefferies
- Sumo Logic price target raised to $11 from $8.50 at Jefferies
- 12/12/22 RBC Capital
- Coupa Software upgraded to Sector Perform from Underperform at RBC Capital
- 07/13/22 Piper Sandler
- Sumo Logic price target lowered to $8 from $10 at Piper Sandler
- 11/21/22
- Zoom Video raises FY23 EPS view to $3.91-$3.94 from $3.66-$3.69
- 11/21/22
- Zoom Video sees Q4 EPS 75c-78c, consensus 80c
- 11/21/22
- Zoom Video reports Q3 EPS $1.07, consensus 84c
- 11/21/22
- Notable companies reporting after market close
- 11/01/22
- Xylem raises FY22 adjusted EPS view to $2.65-$2.75 from $2.50-$2.70
- 11/01/22
- Xylem reports Q3 adjusted EPS 79c, consensus 66c
- 08/02/22
- Xylem raises FY22 adjusted EPS view to $2.50-$2.70 from $2.40-$2.70
- 08/02/22
- Xylem reports Q2 adjusted EPS 66c, consensus 54c
- 01/13/23
- Wells Fargo reports Q4 EPS 67c, consensus 66c
- 01/12/23
- Notable companies reporting before tomorrow's open
- 10/14/22
- Wells Fargo reports Q3 EPS 85c, consensus $1.09
- 10/27/22
- Western Digital sees Q2 EPS (25c)-5c, consensus 34c
- 10/27/22
- Western Digital reports Q1 EPS 20c, consensus 39c
- 08/05/22
- Western Digital sees Q1 EPS 35c-65c, consensus $1.96
- 08/05/22
- Western Digital reports Q4 EPS $1.78, consensus $1.68
- $59.37 /
+12.645 (+27.06%) - 11/03/22
- Wayfair reports Q3 EPS ($2.11), consensus ($2.15)
- 11/02/22
- Notable companies reporting before tomorrow's open
- 08/04/22
- Wayfair sees Q3 revenue below Q2, consensus $3.11B
- 11/10/22
- Tapestry sees FY23 EPS $3.60-$3.70, consensus $3.82
- 11/10/22
- Tapestry reports Q1 EPS 79c, consensus 75c
- 11/09/22
- Notable companies reporting before tomorrow's open
- 01/23/23
- Synchrony reports Q4 EPS $1.26, consensus $1.12
- 10/25/22
- Synchrony reports Q3 EPS $1.47, consensus $1.38
- 12/05/22
- Sumo Logic sees FY23 EPS (36c)-(35c), consensus (55c)
- 12/05/22
- Sumo Logic sees Q4 EPS (9c)-(8c), consensus (17c)
- 12/05/22
- Sumo Logic reports Q3 EPS (4c), consensus (15c)
- 09/20/22
- Sumo Logic sees FY26 revenue $475M-$525M, breakeven operating margin
- 10/25/22
- Spotify reports Q3 Operating loss EUR (228M) vs. profit EUR 75M prior
- 07/27/22
- Spotify sees Q3 total revenue EUR3B, operating loss (EUR218M)
- 07/27/22
- Spotify reports Q2 EPS (EUR0.85) vs. (EUR0.19) last year
- 10/27/22
- Shopify reports Q3 adjusted EPS (2c), consensus (10c)
- 10/26/22
- Notable companies reporting before tomorrow's open
- 07/27/22
- Shopify reports Q2 adjusted EPS (3c), consensus 3c
- 11/02/22
- Qualcomm sees Q1 adjusted EPS adjusted EPS $2.25-$2.45, consensus $3.42
- 11/02/22
- Qualcomm reports Q4 adjusted EPS $3.13, consensus $3.13
- 11/02/22
- Notable companies reporting after market close
- 07/27/22
- Qualcomm sees Q4 adjusted EPS $3.00-$3.30, consensus $3.23
- 12/07/22
- PayPal CEO sees results 'slightly ahead' of EPS guidance
- 11/03/22
- PayPal says plan to deliver FY23 EPS growth of 'no less than 15%'
- 11/03/22
- PayPal sees Q4 EPS $1.18-$1.20, consensus $1.18
- 11/03/22
- PayPal raises FY22 EPS view to $4.07-$4.09, consensus $3.93
- $30.24 /
+7.585 (+33.48%) - 11/08/22
- Pliant Therapeutics reports Q3 EPS (65c), consensus (74c)
- 08/08/22
- Pliant Therapeutics reports Q2 EPS (82c), consensus (81c)
- 01/23/23
- Peoples Bancorp reports Q4 EPS 74c vs. 53c last year
- 10/24/22
- Peoples Bancorp reports Q3 EPS 93c vs. 59c last year
- 07/25/22
- Peoples Bancorp reports Q2 EPS 57c vs. 80c last year
NWBI Northwest Bancshares - 01/23/23
- Northwest Bancshares reports Q4 EPS 27c, consensus 31c
- 07/25/22
- Northwest Bancshares reports Q2 EPS 26c, consensus 22c
- 11/08/22
- Lucid Group reports Q3 EPS (40c), consensus (31c)
- 08/03/22
- Lucid Group reports Q2 EPS (33c), consensus (36c)
- 08/03/22
- Notable companies reporting after market close
- 01/13/23
- JPMorgan reports Q4 EPS $3.57, consensus $3.07
- 10/14/22
- JPMorgan reports Q3 EPS $3.12, consensus $2.88
- 10/26/22
- Ford reports Q3 adjusted EPS 39c, consensus 27c
- 10/26/22
- Notable companies reporting after market close
- 07/27/22
- Ford reports Q2 adjusted EPS 68c, consensus 45c
- 07/27/22
- Notable companies reporting after market close
- 11/17/22
- Dolby says FY23 revenue expected to grow low single digits year-over-year
- 11/17/22
- Dolby sees Q1 EPS 76c-91c, consensus $1.10
- 11/17/22
- Dolby reports Q4 EPS 54c, consensus 60c
- 08/09/22
- Dolby sees FY22 EPS $3.22-$3.37, consensus $3.39
- 11/08/22
- Disney CFO sees FY23 cash content spend in low-$30B range
- 11/08/22
- Disney reports Q4 EPS ex-items 30c, consensus 57c
- 11/08/22
- Notable companies reporting after market close
- 08/10/22
- Disney reports Q3 EPS ex-items $1.09, consensus $1.00
- 01/23/23
- Caesars reports preliminary Q4 revenue $2.81B-$2.83B, consensus $2.77B
- 11/01/22
- Caesars reports Q3 cont ops EPS 24c, consensus 14c
- 08/02/22
- Caesars reports Q2 cont ops EPS 16, consensus 17c
- 08/02/22
- Notable companies reporting after market close
- 11/30/22
- Salesforce raises FY23 EPS view to $4.92-$4.94, consensus $4.73
- 11/30/22
- Salesforce sees Q4 EPS $1.35-$1.37, consensus $1.34
- 11/30/22
- Salesforce reports Q3 EPS $1.40, consensus $1.21
- 11/30/22
- Notable companies reporting after market close
CPRX Catalyst Pharmaceuticals - 11/09/22
- Catalyst Pharmaceuticals raises FY22 revenue view to $205M-$210M from $195-$205M
- 11/09/22
- Catalyst Pharmaceuticals reports Q3 EPS 20c, consensus 19c
- 08/09/22
- Catalyst Pharmaceuticals sees FY22 revenue $195M-$205M, consensus $200.9M
- 08/09/22
- Catalyst Pharmaceuticals reports Q2 EPS 20c, consensus 17c
- 01/23/23
- Bank of Hawaii reports Q4 EPS $1.50, consensus $1.42
- 10/24/22
- Bank of Hawaii reports Q3 EPS $1.28, consensus $1.43
- 07/25/22
- Bank of Hawaii reports Q2 EPS $1.38, consensus $1.34
- 01/23/23
- Bank of Marin reports Q4 EPS 81c, consensus 80c
- 10/24/22
- Bank of Marin reports Q3 EPS 76c, consensus 74c
- 07/25/22
- Bank of Marin reports Q2 EPS 69c, consensus 67c
- 01/23/23
- Baker Hughes reports Q4 adjusted EPS 38c, consensus 40c
- 10/19/22
- Baker Hughes reports Q3 adjusted EPS 26c, consensus 24c
- 08/15/22
- Team to sell Quest Integrity business to Baker Hughes for $280M
- 01/13/23
- Bank of America reports Q4 EPS 85c, consensus 77c
- 10/17/22
- Bank of America reports Q3 EPS 81c, consensus 77c
- $47.29 /
+6.245 (+15.22%) - 11/15/22
- Evoqua Water sees FY23 revenue $$1.81B - $1.89B , consensus $1.8B
- 11/15/22
- Sees FY23 revenue $$1.81B - $1.89B , consensus $1.8B
- 11/15/22
- Evoqua Water reports Q4 EPS 33c, consensus 32c
- 08/02/22
- Evoqua Water reports Q3 EPS 14c, consensus 23c
- 10/27/22
- American Tower reports Q3 AFFO $2.36 , consensus $2.42
- 07/28/22
- American Tower reports Q2 AFFO $$2.59, consensus $2.44
- 11/01/22
- AMD cuts FY22 revenue view to $23.5B +/- $300M from $26.3B +/- $300M
- 11/01/22
- AMD sees Q4 revenue $5.5B +/- $300M, consensus $5.85B
- 11/01/22
- AMD reports Q3 EPS 67c, consensus 68c
- 11/01/22
- Notable companies reporting after market close
- 11/08/22
- Agenus reports Q3 EPS (19c), consensus (19c)
- 08/09/22
- Agenus reports Q2 EPS 17c, consensus (23c)
- 10/27/22
- Apple reports Q4 EPS $1.29, consensus $1.17
- 10/27/22
- Notable companies reporting after market close
- 07/28/22
- Apple reports Q3 EPS $1.20, consensus $1.16
- 07/28/22
- Notable companies reporting after market close
|
|
Syndicate
|
Pliant Therapeutics… Pliant Therapeutics announced that it has commenced an underwritten public offering of $175M of its common stock. Pliant intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and short-term investments, to develop its ongoing and future preclinical and clinical programs including bexotegrast and PLN-101095, further develop its integrin targeting platform, to fund working capital, operating expenses and capital expenditures, and for other general corporate purposes. J.P. Morgan and Piper Sandler are acting as lead book-running managers for the proposed offering. RBC Capital Markets is acting as a book-running manager for the proposed offering. Cantor, Oppenheimer & Co. and H.C. Wainwright & Co. are acting as lead managers for the proposed offering. ShowHide Related Items >><< - $30.18 /
+7.525 (+33.22%) - 01/22/23
- Pliant Therapeutics announces data from INTEGRIS-IPF Phase 2a trial
- 12/15/22
- Pliant Therapeutics receives Orphan Drug Designation from EMA for Bexotegrast
- 09/15/22
- Pliant Therapeutics announces appointment of Knobil to board of directors
- 09/01/22
- Pliant announces 'positive' safety review of PLN-74809 study to treat IPF
- $30.18 /
+7.525 (+33.22%) - 01/23/23 JPMorgan
- Pliant Therapeutics price target raised to $51 from $42 at JPMorgan
- 01/23/23 Cantor Fitzgerald
- Pliant Therapeutics price target raised to $52 from $40 at Cantor Fitzgerald
- 12/13/22 Stifel
- Pliant Therapeutics initiated with a Buy at Stifel
- 12/07/22 JPMorgan
- Pliant Therapeutics initiated with an Overweight at JPMorgan
- $30.18 /
+7.525 (+33.22%) - 11/08/22
- Pliant Therapeutics reports Q3 EPS (65c), consensus (74c)
- 08/08/22
- Pliant Therapeutics reports Q2 EPS (82c), consensus (81c)
|
|
Recommendations
|
JPMorgan analyst Eric… JPMorgan analyst Eric Joseph raised the firm's price target on Pliant Therapeutics to $51 from $42 and keeps an Overweight rating on the shares, citing raised assumptions about the odds of success of bexotegrast following the company's update on the 320mg dose INTEGRIS-IPF data. The clinical opportunity for bexotegrast in IPF is "underappreciated at current levels," the firm contends. ShowHide Related Items >><< - $30.27 /
+7.615 (+33.61%) - 01/22/23
- Pliant Therapeutics announces data from INTEGRIS-IPF Phase 2a trial
- 12/15/22
- Pliant Therapeutics receives Orphan Drug Designation from EMA for Bexotegrast
- 09/15/22
- Pliant Therapeutics announces appointment of Knobil to board of directors
- 09/01/22
- Pliant announces 'positive' safety review of PLN-74809 study to treat IPF
- $30.27 /
+7.615 (+33.61%) - 01/23/23 Cantor Fitzgerald
- Pliant Therapeutics price target raised to $52 from $40 at Cantor Fitzgerald
- 12/13/22 Stifel
- Pliant Therapeutics initiated with a Buy at Stifel
- 12/07/22 JPMorgan
- Pliant Therapeutics initiated with an Overweight at JPMorgan
- 09/01/22 Citi
- Pliant Therapeutics initiated with a Buy at Citi
- $30.27 /
+7.615 (+33.61%) - 11/08/22
- Pliant Therapeutics reports Q3 EPS (65c), consensus (74c)
- 08/08/22
- Pliant Therapeutics reports Q2 EPS (82c), consensus (81c)
|
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 01/23/23
- Xylem falls -9.9%
- 01/23/23
- Xylem falls -8.7%
- 01/23/23
- Evoqua Water jumps 14% to $46.71 after Xylem buyout offer
- 01/23/23
- Xylem to acquire Evoqua Water in $7.5B all-stock transaction
- 01/13/23
- Wells Fargo sees low to mid-single digit loan growth in FY23
- 01/13/23
- Wells Fargo sees FY23 NII growth roughly 10% y/y
- 01/13/23
- Wells Fargo says credit performance remains strong across all businesses
- 10/26/22
- Kioxia, Western Digital open semiconductor fabrication facility Fab7 in Japan
- 08/31/22
- Western Digital, Micron lower in pre-market after Seagate guidance cut
- 08/15/22
- Elliott buys Pinterest, exits Twitter in Q2
- 08/05/22
- Western Digital drops 8% to $45.80 after Q1 guidance misses estimates
- 01/19/23
- Teva announces targets to reduce GHG emissions approved by SBTi
- 01/09/23
- Teva announces nationwide opioids settlement after receiving state support
- 01/06/23
- Alvotech, Teva announce FDA acceptance of AVT04 BLA for review
- 01/23/23
- Synchrony expects decline in net charge-off rate in Q3, normalization path in Q4
- 01/23/23
- Synchrony sees FY23 NIM 15%-15.25%
- 01/23/23
- Synchrony sees long-term ROA 2.5%, ROTCE 28%+
- 01/11/23
- Synchrony reestablishes partnership with Bassett Furniture
- 01/23/23
- Spotify: Alex Norstrom, Gustav Soderstrom appointed co-presidents
- 01/23/23
- Spotify announces reduction in employee base by about 6%
- 01/23/23
- Spotify's Chief Content & Advertising Business Officer Dawn Ostroff to leave
- 01/23/23
- Spotify announces reduction in employee base by about 6%
- 01/12/23
- PayPal's Xoom service expands debit card deposit feature
- 01/09/23
- Netflix names Jeffrey Karbowski as Principal Accounting Officer
- 12/14/22
- ConsenSys teams with PayPal for new way to buy crypto in MetaMask
- 12/07/22
- PayPal expands cryptocurrency buy, sell and hold service to Luxembourg
- $32.84 /
+10.185 (+44.96%) - 01/22/23
- Pliant Therapeutics announces data from INTEGRIS-IPF Phase 2a trial
- 12/15/22
- Pliant Therapeutics receives Orphan Drug Designation from EMA for Bexotegrast
- 09/15/22
- Pliant Therapeutics announces appointment of Knobil to board of directors
- 09/01/22
- Pliant announces 'positive' safety review of PLN-74809 study to treat IPF
- 01/20/23
- Peoples Bancorp board declares special cash dividend of 15c per share
NWBI Northwest Bancshares - 01/23/23
- Northwest Bancshares to reduce workforce about 12%
- 08/18/22
- Northwest Bancshares and Northwest Bank name Louis Torchio as CEO
- 01/12/23
- Lucid Group reports vehicle production up 53% sequentially in Q4 to 3,493
- 12/21/22
- Lucid Group begins deliveries of Lucid Air in Europe
- 12/19/22
- Lucid Group jumps 7% to $7.74 after announcing $1.515B capital raise
- 12/19/22
- Lucid Group announces capital raise of $1.515B
- 01/20/23
- JPMorgan Asset Management receives approval for 100% ownership of China JV
- 01/13/23
- JPMorgan says continues to expect 17% ROTCE in 2023
- 01/13/23
- JPMorgan says targeting potential $12B in share buybacks in 2023
- 01/13/23
- JPMorgan says investment banking pipeline 'relatively robust'
- 01/20/23
- Goldman Sachs down 2% after WSJ report on Fed probe of Marcus unit
- 01/17/23
- Goldman Sachs: May not be able to reach return targets in this environment
- 01/17/23
- Goldman Sachs 'actively engaged' in expense mitigation efforts
- 01/17/23
- Goldman Sachs seeing early signs of consumer credit deterioration, says CFO
- 01/19/23
- Triumph Group awarded two multi-year contracts from Airbus
- 01/18/23
- United sees taking delivery of 92 737 Maxs, 2 787s, 4 A321Neos in 2023
- 01/18/23
- Delta Air Lines executes options for 12 new Airbus A220-300 aircraft
- 01/11/23
- Air Lease announces Q4 activity update
- 12/29/22
- Nevada reports November statewide gaming win down 7.62% to $1.22B
- 12/21/22
- Caesars Sportsbook launches sports betting at Casino Metro
- 12/20/22
- New Jersey reports November gaming revenue up 0.3% to $441.1M
- 12/05/22
- NFL, Genius Sports expand partnership to provide video streams to Caesars
- 01/22/23
- Fly Intel: Top five weekend stock stories
- 01/12/23
- Walmart enters partnership with Salesforce to provide solutions for retailers
- 01/11/23
- Salesforce Security CTO says leaving to join Evolution Equity Partners
- 01/04/23
- Salesforce up 4% to $139.85 after announcing restructuring
CPRX Catalyst Pharmaceuticals - $14.02 /
-6.765 (-32.55%) - 01/23/23
- Catalyst Pharmaceuticals notified of ANDA filing for FIRDAPSE
- 12/19/22
- Catalyst to buy U.S. commercial rights for FYCOMPA from Eisai for $160M
- 09/29/22
- Catalyst Pharmaceuticals announces FDA approval of sNDA for FIRDAPSE
- 09/20/22
- Catalyst Pharmaceuticals CFO Grande sells 90,000 common shares
- 01/20/23
- Baker Hughes reports U.S. rig count down 4 to 771 rigs
- 01/20/23
- Baker Hughes reports U.S. rig count down 4 to 771 rigs
- 01/17/23
- Archer announces term sheet to potentially acquire Baker Hughes unit in U.K.
- 01/13/23
- Baker Hughes reports U.S. rig count up 3 to 775 rigs
- 01/13/23
- Bank of America sees mid-single digit loan growth next year
- 01/13/23
- Bank of America sees Q1 NII around $14.4B
- 01/13/23
- Bank of America sees net charge-offs moving to pre-pandemic levels
- 01/13/23
- Bank of America starting to see stabilization in deposits, says CEO
- 01/23/23
- Evoqua Water rises 13.2%
- 01/23/23
- Evoqua Water rises 11.2%
- 01/23/23
- Evoqua Water rises 13.0%
- 11/20/22
- Fly Intel: Top five weekend stock stories
- 10/27/22
- Stonepeak increases investment in American Tower's data center business
- 10/03/22
- American Tower EVP/General Counsel Ed DiSanto to step down
- 08/31/22
- American Tower, Verizon sign new lease agreement
- 01/23/23
- Agenus presents clinical data from MSS CRC 70 patient cohort of a Phase 1b
- 11/17/22
- Agenus announces expanded data from Phase 1 study of botensilimab, balstilimab
- 11/14/22
- Agenus reports data on botensilimab/balstilimab combination in nine cancer types
- 10/13/22
- GSK vaccine candidate with Agenus' Stimulon shows 82.6% efficacy in RSV
- 01/23/23 Stifel
- Xylem stock reaction to Evoqua deal 'confounding,' says Stifel
- 01/23/23 Raymond James
- Xylem's buyout of Evoqua 'pricey,' with no accretion, says Raymond James
- 01/18/23 Morgan Stanley
- Xylem price target raised to $115 from $105 at Morgan Stanley
- 01/13/23 Mizuho
- Xylem price target raised to $105 from $88 at Mizuho
- 11/16/22 Stifel
- Evoqua Water price target raised to $50 from $43 at Stifel
- 11/16/22 RBC Capital
- Evoqua Water price target raised to $51 from $44 at RBC Capital
- 01/23/23 Deutsche Bank
- Salesforce price target lowered to $190 from $200 at Deutsche Bank
- 01/20/23 Cowen
- Salesforce downgraded to Market Perform at Cowen with disruption risk elevated
- 01/20/23 Cowen
- Salesforce downgraded to Market Perform from Outperform at Cowen
- 01/17/23 DA Davidson
- Salesforce initiated with a Neutral at DA Davidson
- 01/23/23 Piper Sandler
- Spotify workforce reduction to be viewed positively, says Piper Sandler
- 01/17/23 Truist
- Truist sees expectations for Spotify subs and active users as 'reasonable'
- 01/12/23 Jefferies
- Spotify downgraded to Hold from Buy at Jefferies
- 01/05/23 UBS
- Spotify price target lowered to $100 from $142 at UBS
- 01/19/23 Benchmark
- Baker Hughes initiated with a Buy at Benchmark
- 11/18/22 Piper Sandler
- Baker Hughes price target raised to $34 from $30 at Piper Sandler
- 10/26/22 Wells Fargo
- Wells Fargo downgrades 'show me' stock Baker Hughes to neutral
- 10/26/22 Wells Fargo
- Baker Hughes downgraded to Equal Weight from Overweight at Wells Fargo
- 01/10/23 JPMorgan
- Synchrony price target lowered to $36 from $39 at JPMorgan
- 01/06/23 Barclays
- Synchrony downgraded to Equal Weight from Overweight at Barclays
- 12/13/22 BofA
- Synchrony downgraded to Neutral at BofA on consumer concerns
- 12/13/22 BofA
- Discover double downgraded to Underperform at BofA on consumer concerns
- 01/17/23 Citi
- Wells Fargo price target raised to $52 from $48 at Citi
- 01/17/23 Piper Sandler
- Wells Fargo downgraded to Neutral from Overweight at Piper Sandler
- 01/17/23 Jefferies
- Wells Fargo downgraded to Hold from Buy at Jefferies
- 01/11/23 Morgan Stanley
- Wells exit from correspondent 'doesn't move EPS needle,' says Morgan Stanley
- 01/17/23 Citi
- Bank of America price target raised to $38 from $36 at Citi
- 01/17/23 Piper Sandler
- Bank of America downgraded to Underweight from Neutral at Piper Sandler
- 01/10/23 Odeon Capital
- Bank of America upgraded to Buy from Hold at Odeon Capital
- 01/06/23 Deutsche Bank
- Bank of America downgraded to Hold with $36 target at Deutsche Bank
- 01/23/23 Bernstein
- PayPal's 2023 earnings appear largely de-risked, says Bernstein
- 01/18/23 Jefferies
- PayPal price target lowered to $85 from $90 at Jefferies
- 01/18/23 SMBC Nikko
- PayPal downgraded to Underperform from Neutral at SMBC Nikko
- 01/09/23 KeyBanc
- PayPal downgraded to Sector Weight from Overweight at KeyBanc
- 01/18/23 Wells Fargo
- Goldman Sachs price target lowered to $390 from $400 at Wells Fargo
- 01/10/23 Odeon Capital
- Goldman Sachs upgraded to Hold from Sell at Odeon Capital
- 01/06/23 Morgan Stanley
- Goldman Sachs price target lowered to $356 from $384 at Morgan Stanley
- 01/06/23 Deutsche Bank
- Goldman Sachs price target lowered to $345 from $370 at Deutsche Bank
- 01/23/23 Exane BNP Paribas
- Western Digital upgraded to Neutral from Underperform at Exane BNP Paribas
- 01/06/23 Benchmark
- Western Digital upgraded to Hold at Benchmark after Kioxia merger talks report
- 01/06/23 Benchmark
- Western Digital upgraded to Hold from Sell at Benchmark
- 01/05/23 Deutsche Bank
- Western Digital, Kioxia deal makes 'a lot of sense,' says Deutsche Bank
- 01/17/23 Citi
- JPMorgan price target raised to $165 from $150 at Citi
- 01/17/23 Piper Sandler
- JPMorgan price target raised to $157 from $150 at Piper Sandler
- 01/06/23 Deutsche Bank
- JPMorgan downgraded to Hold with $145 target at Deutsche Bank
- 01/06/23 Deutsche Bank
- JPMorgan downgraded to Hold from Buy at Deutsche Bank
- 01/16/23 Berenberg
- Airbus downgraded to Hold from Buy at Berenberg
- 01/11/23 JPMorgan
- Airbus price target lowered to EUR 160 from EUR 170 at JPMorgan
- 12/07/22 Kepler Cheuvreux
- Airbus downgraded to Hold from Buy at Kepler Cheuvreux
- 12/06/22 Jefferies
- Airbus price target lowered to EUR 132 from EUR 140 at Jefferies
- $32.84 /
+10.185 (+44.96%) - 01/23/23 Cantor Fitzgerald
- Pliant Therapeutics price target raised to $52 from $40 at Cantor Fitzgerald
- 12/13/22 Stifel
- Pliant Therapeutics initiated with a Buy at Stifel
- 12/07/22 JPMorgan
- Pliant Therapeutics initiated with an Overweight at JPMorgan
- 09/01/22 Citi
- Pliant Therapeutics initiated with a Buy at Citi
- 01/22/23 Citi
- Lucid Group resumed with a Buy at Citi
- 01/12/23 Cantor Fitzgerald
- Lucid's Q4 production pre-announcement 'encouraging, says Cantor Fitzgerald
- 01/12/23 Evercore ISI
- Evercore ISI says Lucid FY/Q4 production serves as glimmer of execution progress
- 12/15/22 BofA
- Lucid Group resumed with a Buy at BofA
CPRX Catalyst Pharmaceuticals - $14.02 /
-6.765 (-32.55%) - 01/19/23 Truist
- Catalyst Pharmaceuticals price target raised to $22 from $18 at Truist
- 12/21/22 H.C. Wainwright
- Catalyst Pharmaceuticals price target raised to $24 from $18 at H.C. Wainwright
- 12/19/22 Piper Sandler
- Catalyst Pharmaceuticals price target raised to $20 from $18 at Piper Sandler
- 11/10/22 Piper Sandler
- Catalyst Pharmaceuticals price target raised to $18 from $16 at Piper Sandler
- 01/19/23 Jefferies
- Teva downgraded to Hold from Buy at Jefferies
- 01/06/23 Northland
- Alvotech named a top pick for 2023 at Northland
- 11/23/22 Piper Sandler
- Teva price target lowered to $7 from $8 at Piper Sandler
- 11/14/22 JPMorgan
- Teva downgraded to Underweight from Neutral at JPMorgan
- 12/08/22 EF Hutton
- Agenus initiated with a Buy at EF Hutton
- 09/27/22 SMBC Nikko
- Agenus initiated with an Outperform at SMBC Nikko
- 03/03/22 B. Riley
- Agenus price target lowered to $8 from $11 at B. Riley
- 03/02/22 H.C. Wainwright
- Agenus price target raised to $14 from $12 at H.C. Wainwright
- 01/23/23 KeyBanc
- American Tower downgraded to Sector Weight from Overweight at KeyBanc
- 01/22/23 Citi
- American Tower buyout of Cellnex a possibility, says Citi
- 01/13/23 Truist
- American Tower price target lowered to $275 from $325 at Truist
- 01/12/23 Deutsche Bank
- American Tower upgraded to Buy from Hold at Deutsche Bank
- 01/04/23 BofA
- Caesars price target lowered to $50 from $55 at BofA
- 12/14/22 BofA
- Caesars downgraded to Neutral at BofA with growth momentum levelling out
- 12/14/22 BofA
- Caesars downgraded to Neutral from Buy at BofA
- 11/28/22 JPMorgan
- DraftKings downgraded to Underweight from Neutral at JPMorgan
NWBI Northwest Bancshares - 09/29/22 Janney Montgomery Scott
- Janney starts Northwest Bancshares with a Neutral, sees $15 fair value
- 09/29/22 Janney Montgomery Scott
- Northwest Bancshares initiated with a Neutral at Janney Montgomery Scott
- 07/11/22 B. Riley
- Northwest Bancshares price target lowered to $11 from $14 at B. Riley
- 05/06/22 Piper Sandler
- Northwest Bancshares downgraded to Underweight from Neutral at Piper Sandler
- 10/25/22 DA Davidson
- Bank of Hawaii price target lowered to $76 from $80 at DA Davidson
- 07/11/22 Jefferies
- Bank of Hawaii price target lowered to $79 from $87 at Jefferies
- 11/01/22
- Xylem raises FY22 adjusted EPS view to $2.65-$2.75 from $2.50-$2.70
- 11/01/22
- Xylem reports Q3 adjusted EPS 79c, consensus 66c
- 08/02/22
- Xylem raises FY22 adjusted EPS view to $2.50-$2.70 from $2.40-$2.70
- 08/02/22
- Xylem reports Q2 adjusted EPS 66c, consensus 54c
- 01/13/23
- Wells Fargo reports Q4 EPS 67c, consensus 66c
- 01/12/23
- Notable companies reporting before tomorrow's open
- 10/14/22
- Wells Fargo reports Q3 EPS 85c, consensus $1.09
- 10/27/22
- Western Digital sees Q2 EPS (25c)-5c, consensus 34c
- 10/27/22
- Western Digital reports Q1 EPS 20c, consensus 39c
- 08/05/22
- Western Digital sees Q1 EPS 35c-65c, consensus $1.96
- 08/05/22
- Western Digital reports Q4 EPS $1.78, consensus $1.68
- 11/03/22
- Teva backs FY22 EPS view $2.40-$2.60, consensus $2.50
- 11/03/22
- Teva reports Q3 EPS 59c, consensus 62c
- 07/26/22
- Teva backs FY22 EPS view of $2.40-$2.60, consensus $2.46
- 07/26/22
- Teva reports Q2 EPS 68c, consensus 57c
- 01/23/23
- Synchrony reports Q4 EPS $1.26, consensus $1.12
- 10/25/22
- Synchrony reports Q3 EPS $1.47, consensus $1.38
- 10/25/22
- Spotify reports Q3 Operating loss EUR (228M) vs. profit EUR 75M prior
- 07/27/22
- Spotify sees Q3 total revenue EUR3B, operating loss (EUR218M)
- 07/27/22
- Spotify reports Q2 EPS (EUR0.85) vs. (EUR0.19) last year
- 12/07/22
- PayPal CEO sees results 'slightly ahead' of EPS guidance
- 11/03/22
- PayPal says plan to deliver FY23 EPS growth of 'no less than 15%'
- 11/03/22
- PayPal sees Q4 EPS $1.18-$1.20, consensus $1.18
- 11/03/22
- PayPal raises FY22 EPS view to $4.07-$4.09, consensus $3.93
- $32.84 /
+10.185 (+44.96%) - 11/08/22
- Pliant Therapeutics reports Q3 EPS (65c), consensus (74c)
- 08/08/22
- Pliant Therapeutics reports Q2 EPS (82c), consensus (81c)
- 01/23/23
- Peoples Bancorp reports Q4 EPS 74c vs. 53c last year
- 10/24/22
- Peoples Bancorp reports Q3 EPS 93c vs. 59c last year
- 07/25/22
- Peoples Bancorp reports Q2 EPS 57c vs. 80c last year
NWBI Northwest Bancshares - 01/23/23
- Northwest Bancshares reports Q4 EPS 27c, consensus 31c
- 07/25/22
- Northwest Bancshares reports Q2 EPS 26c, consensus 22c
- 11/08/22
- Lucid Group reports Q3 EPS (40c), consensus (31c)
- 11/08/22
- Notable companies reporting after market close
- 08/03/22
- Lucid Group reports Q2 EPS (33c), consensus (36c)
- 08/03/22
- Notable companies reporting after market close
- 01/13/23
- JPMorgan reports Q4 EPS $3.57, consensus $3.07
- 10/14/22
- JPMorgan reports Q3 EPS $3.12, consensus $2.88
- 01/17/23
- Goldman Sachs reports Q4 EPS $3.32, consensus $5.48
- 10/18/22
- Goldman Sachs reports Q3 EPS $8.25, consensus $7.69
- 10/17/22
- Notable companies reporting before tomorrow's open
- 10/28/22
- Airbus reports Q3 revenue EUR 38.1B, EBIT adjusted EUR 3.5B
- 07/27/22
- Airbus reports Q2 adjusted EBIT EUR 1.38B vs. EUR 2.01B last year
- 01/23/23
- Caesars reports preliminary Q4 revenue $2.81B-$2.83B, consensus $2.77B
- 11/01/22
- Caesars reports Q3 cont ops EPS 24c, consensus 14c
- 08/02/22
- Caesars reports Q2 cont ops EPS 16, consensus 17c
- 08/02/22
- Notable companies reporting after market close
- 11/30/22
- Salesforce raises FY23 EPS view to $4.92-$4.94, consensus $4.73
- 11/30/22
- Salesforce sees Q4 EPS $1.35-$1.37, consensus $1.34
- 11/30/22
- Salesforce reports Q3 EPS $1.40, consensus $1.21
- 11/30/22
- Notable companies reporting after market close
CPRX Catalyst Pharmaceuticals - $14.02 /
-6.765 (-32.55%) - 11/09/22
- Catalyst Pharmaceuticals raises FY22 revenue view to $205M-$210M from $195-$205M
- 11/09/22
- Catalyst Pharmaceuticals reports Q3 EPS 20c, consensus 19c
- 08/09/22
- Catalyst Pharmaceuticals sees FY22 revenue $195M-$205M, consensus $200.9M
- 08/09/22
- Catalyst Pharmaceuticals reports Q2 EPS 20c, consensus 17c
- 01/23/23
- Bank of Hawaii reports Q4 EPS $1.50, consensus $1.42
- 10/24/22
- Bank of Hawaii reports Q3 EPS $1.28, consensus $1.43
- 07/25/22
- Bank of Hawaii reports Q2 EPS $1.38, consensus $1.34
- 01/23/23
- Bank of Marin reports Q4 EPS 81c, consensus 80c
- 10/24/22
- Bank of Marin reports Q3 EPS 76c, consensus 74c
- 07/25/22
- Bank of Marin reports Q2 EPS 69c, consensus 67c
- 01/23/23
- Baker Hughes reports Q4 adjusted EPS 38c, consensus 40c
- 10/19/22
- Baker Hughes reports Q3 adjusted EPS 26c, consensus 24c
- 08/15/22
- Team to sell Quest Integrity business to Baker Hughes for $280M
- 01/13/23
- Bank of America reports Q4 EPS 85c, consensus 77c
- 10/17/22
- Bank of America reports Q3 EPS 81c, consensus 77c
- 11/15/22
- Evoqua Water sees FY23 revenue $$1.81B - $1.89B , consensus $1.8B
- 11/15/22
- Sees FY23 revenue $$1.81B - $1.89B , consensus $1.8B
- 11/15/22
- Evoqua Water reports Q4 EPS 33c, consensus 32c
- 08/02/22
- Evoqua Water reports Q3 EPS 14c, consensus 23c
- 10/27/22
- American Tower reports Q3 AFFO $2.36 , consensus $2.42
- 07/28/22
- American Tower reports Q2 AFFO $$2.59, consensus $2.44
- 11/08/22
- Agenus reports Q3 EPS (19c), consensus (19c)
- 08/09/22
- Agenus reports Q2 EPS 17c, consensus (23c)
|
